Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obesity is linked to disease severity in moderate to severe atopic dermatitis-Data from the prospective observational TREATgermany registry.
Traidl S, Hollstein MM, Kroeger N, Fischer S, Heratizadeh A, Heinrich L, Kind B, Siegels D, Abraham S, Schäfer T, Augustin M, Harder I, Pinter A, Schäkel K, Wollenberg A, Ertner K, Ramaker-Brunke J, Bong A, Quist S, Gorriahn-Maiterth H, Schenck F, Sticherling M, Effendy I, Schwarz B, Handrick C, Asmussen A, Weidinger S, Schmitt J, Werfel T; TREATgermany Study Group. Traidl S, et al. Among authors: weidinger s. J Eur Acad Dermatol Venereol. 2024 Apr 25. doi: 10.1111/jdv.20042. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38661511
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
Sander N, Stölzl D, Fonfara M, Hartmann J, Harder I, Suhrkamp I, Jakaša I, van den Bogaard E, van Vlijmen-Willems I, Szymczak S, Rodriguez E, Gerdes S, Weidinger S. Sander N, et al. Among authors: weidinger s. Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093/bjd/ljae138. Online ahead of print. Br J Dermatol. 2024. PMID: 38531691
Treatment of moderate-to-severe atopic dermatitis with baricitinib: Results from an interim analysis of the TREATgermany registry.
Traidl S, Heinrich L, Siegels D, Heratizadeh A, Kind B, Haufe E, Abraham S, Schäfer T, Augustin M, Harder I, Pinter A, Schäkel K, Wollenberg A, Ertner K, Ramaker-Brunke J, Bong A, Quist S, Gorriahn-Maiterth H, Schenck F, Sticherling M, Effendy I, Schwarz B, Handrick C, Asmussen A, Weidinger S, Schmitt J, Werfel T; TREATgermany study group. Traidl S, et al. Among authors: weidinger s. J Eur Acad Dermatol Venereol. 2024 Mar 28. doi: 10.1111/jdv.19979. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38545850 No abstract available.
Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
Ramessur R, Dand N, Langan SM, Saklatvala J, Fritzsche MC, Holland S, Arents BWM, McAteer H, Proctor A, McMahon D, Greenwood M, Buyx AM, Messer T, Weiler N, Hicks A, Hecht P, Weidinger S, Ndlovu MN, Chengliang D, Hübenthal M, Egeberg A, Paternoster L, Skov L, De Jong EMGJ, Middelkamp-Hup MA, Mahil SK, Barker JN, Flohr C, Brown SJ, Smith CH. Ramessur R, et al. Among authors: weidinger s. Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093/bjd/ljae080. Online ahead of print. Br J Dermatol. 2024. PMID: 38419411
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S. Kwatra SG, et al. Among authors: weidinger s. Acta Derm Venereol. 2024 May 6;104:adv18452. doi: 10.2340/actadv.v104.18452. Acta Derm Venereol. 2024. PMID: 38708991 Free PMC article.
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
Hebert AA, Flohr C, Hong HC, Irvine AD, Pierce E, Elmaraghy H, Pillai S, Dawson Z, Chen S, Armengol C, Siegfried E, Weidinger S. Hebert AA, et al. Among authors: weidinger s. J Dermatolog Treat. 2024 Dec;35(1):2324833. doi: 10.1080/09546634.2024.2324833. Epub 2024 May 12. J Dermatolog Treat. 2024. PMID: 38735650 Free article. Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
386 results